Lataa...
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
PURPOSE: Parallel activation of the phosphatidylinositol 3-kinase–mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two pathways have yet to be cotargeted in humans. We performed a phase I study to evaluate the safety an...
Tallennettuna:
| Julkaisussa: | JCO Precis Oncol |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Clinical Oncology
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7446411/ https://ncbi.nlm.nih.gov/pubmed/32913986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00189 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|